Page 2 - Continued Execution News Today

Continued Operating Momentum, with Revenues Up 9% Sequentially and 44% Year-over-YearSigned Multi-Million-Dollar Contract Renewal with Major U.S....

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE / May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial...

Extended Stay America Files Preliminary Proxy Statement and Reiterates Board and Management Support for Acquisition Agreement With Blackstone and Starwood Capital Extended Stay America, Inc. Transaction Provides Immediate, Certain and Compelling Value to Shareholders Represents Superior Value to the Continued Execution of Extended Stay’s Strategic Plan on a Time and Risk-Adjusted Basis Marks Culmination of Thorough Actions to Explore Value-Enhancing Alternatives CHARLOTTE, N.C., April 13...

Australis Provides Acquisition and Corporate Update News provided by Share this article Clearview Capital Consult Appointed for IR LAS VEGAS, Feb. 9, 2021 /PRNewswire/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company") today announced that the Company is progressing well towards completion of the previously announced proposed acquisitions of ALPS and Green Therapeutics LLC ("GT"). Acquisitions Update The Company is working towards the completion of the acquisition of a...